Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis

Finance-Focused Summary (LLY Stock Analysis)

• Eli Lilly (LLY) is gaining share in the oral GLP-1 weight-loss market (entered second, but expanding rapidly).
  • Market share: >30% by new prescriptions in oral GLP-1; over 36,000 people.

Zepbound: Treatment Cost Savings

• Zepbound (Lilly’s weight-loss drug) is presented as offering treatment cost savings.
  • Up to $600 per month per person after 12 months (with the study also referenced after 6 months).
  • The claim suggests fewer downstream health issues, which could mean lower medical treatment costs, even if patients pay out-of-pocket.

Revenue Growth

• Lilly’s revenue is described as having skyrocketed to ~$80B (past 12 months), up from:
  • ~$30B (2022)
  • ~$8B (2020)
• Framed as a nearly 10x increase in <10 years, described as rare in pharma.

Profitability / Margins

• Operating margin: 49.7% over the past 12 months (record).
• Compared to ~15% in 2017.
• Operating profit margin is described as having more than tripled while revenue grew >10x.

Strategic Product Expansion (Portfolio Construction Idea)

• The strategy points toward more individualized treatments instead of one-size-fits-all.
• Current offering described as:
  • one injectable
  • one oral pill
• Planned expansion is described based on patient priorities:
  • Best tolerability (least administration discomfort)
  • Maximum weight loss (accepting more side effects like nausea and stomach pain)

Capital Efficiency / Returns

• ROIC (return on invested capital): 37% over the past 12 months, up from ~10% in 2017.

Competitive Positioning

• Outperformance vs Novo Nordisk and Pfizer is attributed to Lilly spending a larger % of revenue on R&D over the past decade.
• Mentions that the R&D is efficient (not “wasteful”) relative to peers.

---

Valuation & Performance Metrics (Explicit Numbers / Claims)

Valuation

• Forward P/E: 24
• Described as not extreme and closer to the lower end of the stock’s forward P/E range over the past 3 years.

Free Cash Flow (FCF) Model Update

• The author revised FCF estimates upward by capturing more oral market share than previously expected.
• Intrinsic value estimate: $1,494 per share
• Current market price referenced: $1,151
• Implied upside: ~30% over the next 12–18 months

Stated Action / Recommendation

• Bullish on LLY
• Presenter says they bought earlier this year and plan to buy more.

---

Risk / Time Horizon & Cautions

• Time horizon emphasized: long-term investing (years to decades), not short-term trading.
• Risk disclaimer: “Nothing is guaranteed in the market”; investments involve risk.
• Pharma cyclicality risk: some drugs become hits while others can fail; growth periods may alternate with stagnation.

---

Instruments / Companies / Sectors Mentioned

• Ticker: LLY (Eli Lilly)
• Peers/mentioned companies: Novo Nordisk, Pfizer
• AI analogy companies mentioned: Nvidia, Micron
• Drug/therapy: Zepbound (GLP-1 / weight loss)
• Sector: Pharmaceuticals; weight loss / GLP-1 market
• No macro asset classes (e.g., bonds/commodities/ETFs) explicitly mentioned.

---

Methodology Framework (High-Level)

• FCF valuation model update
  1. Reassess assumptions that Lilly is capturing more oral market share than previously expected.
  2. Revise free cash flow estimates upward.
  3. Derive an estimated fair value per share ($1,494) vs current price ($1,151).
  4. Translate into expected upside (~30%) over 12–18 months.

---

Disclosures / Sponsors

• Video sponsored by The Motley Fool (includes fool.com/parkev and “10 best deals to buy now”).
• Presenter includes a standard caution that nothing is guaranteed.

---

Presenters / Sources

• The Motley Fool (sponsor)
• Unnamed author/presenter of the analysis (no individual name provided in the subtitles).